Jump to content
RemedySpot.com

Viral hepatitis B - Lancet

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 04

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

Lancet. 2003 Dec 20;362(9401):2089-94.

Viral hepatitis B.

Lai CL, Ratziu V, Yuen MF, Poynard T.

Department of Medicine, University of Hong Kong, Queen Hospital, Hong

Kong, People's Republic of China. hrmelcl@...

More than 400 million people worldwide are chronically infected by the

hepatitis B virus. The virus is responsible for more than 300000 cases of

liver cancer every year and for similar numbers of gastrointestinal

haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis

and treatment of this virus. Hepatitis B vaccine reduces incidence of liver

cancer. As with hepatitis C, advances have been made in molecular virology,

especially for naturally occurring and treatment-induced mutant viruses. The

clinical significance of low viral load and genotypes are also under

investigation. Currently available monotherapies-interferon, lamivudine, and

adefovir dipivoxil-very rarely eradicate the virus, but greatly reduce its

replication, necroinflammatory histological activity, and progression of

fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse

cirrhosis of the liver.

Publication Types:

Review

Review, Tutorial

PMID: 14697813 [PubMed - indexed for MEDLINE]

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Lancet. 2003 Dec 20;362(9401):2089-94.

Viral hepatitis B.

Lai CL, Ratziu V, Yuen MF, Poynard T.

Department of Medicine, University of Hong Kong, Queen Hospital, Hong

Kong, People's Republic of China. hrmelcl@...

More than 400 million people worldwide are chronically infected by the

hepatitis B virus. The virus is responsible for more than 300000 cases of

liver cancer every year and for similar numbers of gastrointestinal

haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis

and treatment of this virus. Hepatitis B vaccine reduces incidence of liver

cancer. As with hepatitis C, advances have been made in molecular virology,

especially for naturally occurring and treatment-induced mutant viruses. The

clinical significance of low viral load and genotypes are also under

investigation. Currently available monotherapies-interferon, lamivudine, and

adefovir dipivoxil-very rarely eradicate the virus, but greatly reduce its

replication, necroinflammatory histological activity, and progression of

fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse

cirrhosis of the liver.

Publication Types:

Review

Review, Tutorial

PMID: 14697813 [PubMed - indexed for MEDLINE]

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Lancet. 2003 Dec 20;362(9401):2089-94.

Viral hepatitis B.

Lai CL, Ratziu V, Yuen MF, Poynard T.

Department of Medicine, University of Hong Kong, Queen Hospital, Hong

Kong, People's Republic of China. hrmelcl@...

More than 400 million people worldwide are chronically infected by the

hepatitis B virus. The virus is responsible for more than 300000 cases of

liver cancer every year and for similar numbers of gastrointestinal

haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis

and treatment of this virus. Hepatitis B vaccine reduces incidence of liver

cancer. As with hepatitis C, advances have been made in molecular virology,

especially for naturally occurring and treatment-induced mutant viruses. The

clinical significance of low viral load and genotypes are also under

investigation. Currently available monotherapies-interferon, lamivudine, and

adefovir dipivoxil-very rarely eradicate the virus, but greatly reduce its

replication, necroinflammatory histological activity, and progression of

fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse

cirrhosis of the liver.

Publication Types:

Review

Review, Tutorial

PMID: 14697813 [PubMed - indexed for MEDLINE]

Link to comment
Share on other sites
Guest guest

Guest guest

Posted
Posted

Lancet. 2003 Dec 20;362(9401):2089-94.

Viral hepatitis B.

Lai CL, Ratziu V, Yuen MF, Poynard T.

Department of Medicine, University of Hong Kong, Queen Hospital, Hong

Kong, People's Republic of China. hrmelcl@...

More than 400 million people worldwide are chronically infected by the

hepatitis B virus. The virus is responsible for more than 300000 cases of

liver cancer every year and for similar numbers of gastrointestinal

haemorrhage and ascites. Major breakthroughs have been achieved in diagnosis

and treatment of this virus. Hepatitis B vaccine reduces incidence of liver

cancer. As with hepatitis C, advances have been made in molecular virology,

especially for naturally occurring and treatment-induced mutant viruses. The

clinical significance of low viral load and genotypes are also under

investigation. Currently available monotherapies-interferon, lamivudine, and

adefovir dipivoxil-very rarely eradicate the virus, but greatly reduce its

replication, necroinflammatory histological activity, and progression of

fibrosis. Lamivudine, and presumably other nucleoside analogues, can reverse

cirrhosis of the liver.

Publication Types:

Review

Review, Tutorial

PMID: 14697813 [PubMed - indexed for MEDLINE]

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...